Featured XIENCE short DAPT trials

  • Watch global experts panel discussion about STOPDAPT 2 HBR
  • Watch late breaking STOPDAPT 2 HBR sub-analysis results
  • Watch global experts discuss the results and learn more about XIENCE's Short DAPT program
  • XIENCE – Protecting Patients with Short DAPT Needs

XIENCE – Protecting Patients with Short DAPT Needs

In the late breaking STOPDAPT2 trial1, a 3000-patient RCT, 1-month DAPT demonstrated superior safety over 12-month DAPT in the primary endpoint – Net Adverse Cardiovascular Events (NACE) – (cardiovascular death, MI, Def ST, Stroke, or TIMI major/minor bleeding) in patients treated with XIENCE.
 XIENCE, is supported by the largest and most comprehensive body of evidence for short DAPT, with over 19,000 patients2 analyzed.



Primary non-inferiority analysis at 12 months. Secondary superiority analysis at 60 months.

Learn more about STOPDAPT 2 at:https://clinicaltrials.gov/ct2/show/NCT02619760?term=stopdapt2&rank=1

*NACE is a composite of CV death, Ml, ST, Stroke. TIM I major/minor bleeding (Net Clinical Benefit)

Abbott has established the XIENCE Short DAPT program of clinical trials, which focuses on high risk bleeding patients. Shortening DAPT (Dual AntiPlatelet Therapy) duration may be particularly important for patients at higher risk of bleeding, e.g., older patients, patients taking anticoagulants, and patients with anemia or renal disease.

The studies in the XIENCE Short DAPT program are:

Dr. Mehran is global principal investigator of the XIENCE 90 trial. The principal investigator of the XIENCE 28 study is Marco Valgimigli, MD.

Currently physicians have no clear guidance when weighing their patients’ needs and risk factors—their need for DAPT to reduce ischemic complications after percutaneous coronary intervention (PCI) and, for many patients, their bleeding risk while on prolonged DAPT.

“We have a lot of patients in whom DAPT cannot be longer than 1 [month] and we need to provide some answers to them.” 


Find out more about both the XIENCE 90 and XIENCE 28 Global trials. You may also sign up to receive updates on the latest XIENCE study results as they become available.

Get the latest data

Sign up to receive the latest about XIENCE study results as they become available.

Sign up

1. Watanabe et al., ACC 2019.

2. SPIRIT II (n=223), SPIRIT III (n=669), SPIRIT IV (n=2,458), SPIRIT V (n=1,662), SPIRIT Women (n=1,506), XIENCE V USA (n=6,516), XIENCE V India (n=931), COMPARE (n=897), STOPDAPT (n=1,525), STOPDAPT2 (n=3,009)

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?


The website you have requested is a product-specific website that is NOT intended for U.S. residents. This web content is exclusively reserved for health care professionals in countries with applicable health authority product registrations.

If you are a resident of a country other than those to which the site is directed, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

Do you wish to continue to visit this website?